Search Result

Results for "

dihydroorotate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Dihydroorotate Dehydrogenase (75) Apoptosis (3) Autophagy (4) Bacterial (3) Caspase (1) CHIKV (1) Dengue Virus (2) DNA/RNA Synthesis (34) Drug Intermediate (1) Endogenous Metabolite (10) Ferroptosis (1) Flavivirus (1) Fluorescent Dye (1) Fungal (3) FXR (2) HCV (1) HIV (1) HPV (1) Influenza Virus (4) Interleukin Related (2) Isotope-Labeled Compounds (3) Lactate Dehydrogenase (2) MDM-2/p53 (3) Nucleoside Antimetabolite/Analog (5) Parasite (14) Prostaglandin Receptor (2) Reactive Oxygen Species (ROS) (1) Reference Standards (8) ROS Kinase (1) SARS-CoV (5) Sirtuin (3) VEGFR (1) Virus Protease (3)
By Research Areas:	Cancer (31) Infection (39) Inflammation/Immunology (18) Metabolic Disease (6)

By Targets:

Dihydroorotate Dehydrogenase (75)

Apoptosis (3)

Autophagy (4)

Bacterial (3)

Caspase (1)

CHIKV (1)

Dengue Virus (2)

DNA/RNA Synthesis (34)

Drug Intermediate (1)

Endogenous Metabolite (10)

Ferroptosis (1)

Flavivirus (1)

Fluorescent Dye (1)

Fungal (3)

FXR (2)

HCV (1)

HIV (1)

HPV (1)

Influenza Virus (4)

Interleukin Related (2)

Isotope-Labeled Compounds (3)

Lactate Dehydrogenase (2)

MDM-2/p53 (3)

Nucleoside Antimetabolite/Analog (5)

Parasite (14)

Prostaglandin Receptor (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (8)

ROS Kinase (1)

SARS-CoV (5)

Sirtuin (3)

VEGFR (1)

Virus Protease (3)

By Research Areas:

Cancer (31)

Infection (39)

Inflammation/Immunology (18)

Metabolic Disease (6)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Dihydroorotate Dehydrogenase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0083

Leflunomide Maximum Cited Publications 17 Publications Verification HWA486; RS-34821; SU101	Dihydroorotate Dehydrogenase Endogenous Metabolite Bacterial	Cancer
Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

HY-108325

Brequinar Maximum Cited Publications 28 Publications Verification DUP785; NSC 368390	Dihydroorotate Dehydrogenase SARS-CoV Virus Protease DNA/RNA Synthesis	Infection Inflammation/Immunology Cancer
Brequinar (DUP785) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC₅₀ of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-SARS2 activity.

HY-N0157

Orotic acid 3 Publications Verification 6-Carboxyuracil; Vitamin B13	Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

HY-112645

BAY-2402234 10+ Cited Publications	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
BAY-2402234 is a selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies.

HY-W015495

L-Dihydroorotic acid 1 Publications Verification	Endogenous Metabolite Dihydroorotate Dehydrogenase	Others
L-Dihydroorotic acid is an important intermediate in the metabolism of orotic acid and a substrate of dihydroorotate dehydrogenase (DHODH). L-Dihydroorotic acid can reversibly hydrolyze to yield the acyclic L-ureidosuccinic acid by dihydrowhey enzyme .

HY-104029

Olorofim F901318	Fungal Dihydroorotate Dehydrogenase	Infection
Olorofim (F901318) selectively inhibits fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the pyrimidine biosynthesis pathway. Olorofim (F901318). Olorofim exhibits excellent activity against A. fumigatus and other Aspergillus spp. .

HY-124593

PTC299 5 Publications Verification Emvododstat	VEGFR Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies .

HY-15510

Tenovin-6 5 Publications Verification	MDM-2/p53 Dihydroorotate Dehydrogenase Sirtuin Autophagy	Cancer
Tenovin-6, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC₅₀s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 also inhibits dihydroorotate dehydrogenase (DHODH) .

HY-14908

Vidofludimus 4 Publications Verification 4sc-101; SC12267	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .

HY-129239

Farudodstat 4 Publications Verification ASLAN003	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Apoptosis	Cancer
Farudodstat (ASLAN003) is an orally active and potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC₅₀ of 35 nM for human DHODH enzyme. Farudodstat inhibits protein synthesis via activation of AP-1 transcription factors. Farudodstat induces apoptosis and substantially prolongs survival in acute myeloid leukemia (AML) xenograft mice .

HY-148396

UCK2 Inhibitor-3	DNA/RNA Synthesis	Infection Cancer
UCK2 Inhibitor-3 is a non-competitive inhibitor of uridine-cytidine kinase 2 (UCK2, a pyrimidine salvage enzyme) with an IC₅₀ value of 16.6 μM. UCK2 can replace dihydroorotate dehydrogenase (DHODH), in a certain extent, in infected or rapidly dividing cells to continue efficient uridine salvage. UCK2 Inhibitor-3 also inhibits DNA polymerase eta and kappa with IC₅₀s of 56 μM and 16 μM .

HY-100184

DSM265 2 Publications Verification	Dihydroorotate Dehydrogenase Parasite	Infection
DSM265 is a long-duration inhibitor of P. falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC₅₀ of 8.9 nM. DSM265 can also inhibit the growth of Pf3D7 parasites with an EC₅₀ of 4.3 nM .

HY-139189

JNJ-74856665 DHODH-IN-16	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
JNJ-74856665 (DHODH-IN-16) is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 0.396 nM for human DHODH .

HY-100688

ML390 1 Publications Verification	Dihydroorotate Dehydrogenase	Cancer
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models .

HY-13423

Tenovin-1 5 Publications Verification	MDM-2/p53 Dihydroorotate Dehydrogenase Sirtuin Autophagy	Cancer
Tenovin-1, a p53 activator, protects p53 from MDM2-mediated degradation. Tenovin-1 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also a dihydroorotate dehydrogenase (DHODH) inhibitor .

HY-137463

AG-636 2 Publications Verification	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
AG-636 is a potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 17 nM. AG-636 has strong anticancer effects .

HY-15510B

Tenovin-6 Hydrochloride 5 Publications Verification	MDM-2/p53 Dihydroorotate Dehydrogenase Sirtuin Autophagy	Cancer
Tenovin-6 Hydrochloride, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 Hydrochloride inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC₅₀s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 Hydrochloride also inhibits dihydroorotate dehydrogenase (DHODH) .

HY-135658

hDHODH-IN-1	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
hDHODH-IN-1 is a *human dihydroorotate* dehydrogenase (hDHODH)** inhibitor. hDHODH-IN-1 has anti-inflammatory effect .

HY-135282

DHODH-IN-1	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
DHODH-IN-1 (compound 18d) is a potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC₅₀ of 25 nM. DHODH-IN-1 is an inhibitor of pyrimidine biosynthesis pathway .

HY-101813

Laflunimus HR325	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Prostaglandin Receptor	Inflammation/Immunology
Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC₅₀ values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor .

HY-N0157R

Orotic acid (Standard) 6-Carboxyuracil (Standard); Vitamin B13 (Standard)	Reference Standards Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Orotic acid (Standard) is the analytical standard of Orotic acid. This product is intended for research and analytical applications. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

HY-156442

MEDS433	Lactate Dehydrogenase	Infection
MEDS433 is a potent inhibitor of *human dihydroorotate* dehydrogenase (hDHODH) with an IC₅₀** of 1.2 nM. MEDS433 exerts a potent antiviral activity against RSV-A and RSV-B in the one-digit nanomolar range. MEDS433 induces the expression of antiviral proteins encoded by interferon stimulated genes (ISGs) able to reduce RSV replication .

HY-N7961

(E/Z)-Ginkgolic acid C17:2	Dihydroorotate Dehydrogenase	Others
(E/Z)-Ginkgolic acid C17:2, isolated from Ginkgo biloba, can bind with human dihydroorotate dehydrogenase (DHODH) tightly .

HY-135570

hDHODH-IN-3	Influenza Virus Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
hDHODH-IN-3 (compound 21d) is a *human dihydroorotate* dehydrogenase (HsDHODH) inhibitor, inhibits measles virus replication with a pMIC₅₀** value of 8.6 .

HY-128787

hDHODH-IN-4	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Influenza Virus	Infection
hDHODH-IN-4 is a potent human dihydroorotate dehydrogenase (DHODH) inhibitor, with a pIC₅₀ of 7.8 for human recombinant DHODH. hDHODH-IN-4 inhibits measles virus replication, with a pMIC₅₀ of 8.8 .

HY-132174

CHIKV-IN-2	Flavivirus Dengue Virus CHIKV Dihydroorotate Dehydrogenase	Infection
CHIKV-IN-2 is a potent inhibitor against Chikungunya virus (CHIKV), with excellent cellular antiviral activity (EC₉₀=270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular target Dihydroorotate Dehydrogenase (DHODH), which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools .

HY-135664

hDHODH-IN-5	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-7 is a human dihydroorotate dehydrogenase (DHODH) inhibitor, with an IC₅₀ of 0.91 μM. DHODH-IN-7 induces differentiation in acute myeloid leukemia .

HY-149642

hDHODH-IN-13	Dihydroorotate Dehydrogenase	Others
hDHODH-IN-13 (compound w2) is an inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC₅₀ value of 173.4 nM. hDHODH-IN-13 can be used in the research of IBD .

HY-135648

PfDHODH-IN-1	Parasite Lactate Dehydrogenase DNA/RNA Synthesis	Infection
PfDHODH-IN-1 is an analogue of the active metabolite of Leflunomide. PfDHODH-IN-1 is a Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor. PfDHODH-IN-1 has antimalarial activity .

HY-135678

DHODH-IN-14	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-14 (Compound 7l) is a hydroxyfurazan analog of A771726. DHODH-IN-14 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 0.49 μM for rat liver DHODH. DHODH-IN-14 can be used for rheumatoid arthritis .

HY-W015495R

L-Dihydroorotic acid (Standard)	Reference Standards Endogenous Metabolite Dihydroorotate Dehydrogenase	Others
L-Dihydroorotic acid (Standard) is an analytical reference standard for L-Dihydroorotic acid. This product is used for research and analytical applications. L-Dihydroorotic acid is an important intermediate in the metabolism of orotic acid and a substrate of dihydroorotate dehydrogenase (DHODH). L-Dihydroorotic acid can reversibly hydrolyze to yield the acyclic L-ureidosuccinic acid by dihydrowhey enzyme .

HY-N0157A

Orotic acid zinc 3 Publications Verification 6-Carboxyuracil zinc; Vitamin B13 zinc	Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Orotic acid (zinc), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid (zinc) is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid (zinc) can induce hepatic steatosis and hepatomegaly in rats .

HY-170780

DSM1465	Parasite Dihydroorotate Dehydrogenase	Infection
DSM1465 (Compound 82) is a potent, selective inhibitor of P. falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC₅₀ value of 15 nM, inhibits P. falciparum 3D7 (Pf3D7) parasites with an EC₅₀ value of 1.4 nM. DSM1465 shows potent in vivo activity in the humanized P. falciparum mouse model .

HY-132170

DSM502	Dihydroorotate Dehydrogenase Parasite	Infection
DSM502 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM502 exhibits nanomolar potency againsts Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs .

HY-B0083S

Leflunomide-d4	Dihydroorotate Dehydrogenase	Cancer
Leflunomide-d₄ (HWA486-d₄) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent .

HY-135619

DHODH-IN-4	Parasite Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection Inflammation/Immunology
DHODH-IN-4 (compound 17) is a human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitor, with IC₅₀ values of 4 μM and 0.18 μM for PfDHODH and HsDHODH, respectively. DHODH-IN-4 (compound 17) possess antimalarial activity .

HY-32757

5-Bromo-2-fluoro-3-methylpyridine 5-Bromo-2-fluoro-3-picoline	Drug Intermediate	Others
5-Bromo-2-fluoro-3-methylpyridine (5-Bromo-2-fluoro-3-picoline) is a drug synthesis intermediate that can be used to synthesize an inhibitor of dihydroorotate dehydrogenase (DHODH) .

HY-132171A

DSM705 hydrochloride	Dihydroorotate Dehydrogenase Parasite	Infection
DSM705 hydrochloride, an orally active antimalarial compound, is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM705 hydrochloride exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites (IC₅₀=95, 52 nM for P. falciparum and P. vivax DHODH, respectively), with no inhibition of mammalian DHODHs .

HY-N0157S1

Orotic acid-13C,15N2 monohydrate 6-Carboxyuracil-13C,15N2 monohydrate; Vitamin B13-13C,15N2 monohydrate	Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Orotic acid- ¹³C, ¹⁵N₂ (monohydrate) is the ¹³C and ¹⁵N labeled Orotic acid . Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

HY-114215

DSM-421	Dihydroorotate Dehydrogenase Parasite	Infection
DSM-421 is an orally active Dihydroorotate dehydrogenase inhibitor. DSM-421 has antiplasmodium activity .

HY-135667

hDHODH-IN-7	DNA/RNA Synthesis Influenza Virus Dihydroorotate Dehydrogenase	Infection
DHODH-IN-9 (Compound 10k) is an azine-bearing analogue and is a *human dihydroorotate* dehydrogenase** inhibitor. DHODH-IN-9 has antiviral effect with a pMIC₅₀ of 7.4 .

HY-178156

DHODH-IN-31	Dihydroorotate Dehydrogenase SARS-CoV	Infection
DHODH-IN-31 is a human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 0.59 μM. DHODH-IN-31 exhibits antiviral activity. DHODH-IN-31 can be used for the research of infection, such as SARS-CoV-2 .

HY-14908A

Vidofludimus hemicalcium 4sc-101 hemicalcium; SC12267 hemicalcium	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR .

HY-135675

DHODH-IN-11	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-11 (Compound 14b) is a Leflunomide derivative and a weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pK_a of 5.03 .

HY-120924

BRD9185	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite	Infection
BRD9185 is a Dihydroorotate dehydrogenase (DHODH) inhibitor, with an EC₅₀ of 16 nM against multidrug-resistant blood-stage parasites in vitro and is curative after just three doses in a P. berghei mouse model .

HY-132171

DSM705	Dihydroorotate Dehydrogenase Parasite	Infection
DSM705 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM705 exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs. DSM705 is a potent antimalarial compound .

HY-135666

DHODH-IN-8	Parasite Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
DHODH-IN-8 (Compound 27) is an inhibitor of human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) with IC₅₀s of 0.13 μM and 47.4 μM, and K_is of 0.016 μM and 5.6 μM, respectively. DHODH-IN-8 has antimalarial activity .

HY-108325R

Brequinar (Standard) DUP785 (Standard); NSC 368390 (Standard)	Dihydroorotate Dehydrogenase SARS-CoV Virus Protease DNA/RNA Synthesis Reference Standards	Infection Inflammation/Immunology Cancer
Brequinar (Standard) is the analytical standard of Brequinar. This product is intended for research and analytical applications. Brequinar (DUP785) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC50 of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-SARS2 activity.

HY-128660

RYL-634	HCV Dengue Virus Influenza Virus	Infection
RYL-634 is a potent broad-spectrum antiviral agent. RYL-634 exerts its antiviral effect by inhibiting the activity of human dihydroorotate dehydrogenase (HsDHODH) and blocking the supply of pyrimidines required for viral replication. RYL-634 shows significant inhibition against many viruses, with the EC₅₀ values against DENV, ZIKV, EV71, HCV and HIV are 7 nM, 20 nM, 4 nM, 5 nM and 13 nM respectively. RYL-634 can be used for the study of various virus infection-related diseases .

HY-178941

DHODH-IN-32	Dihydroorotate Dehydrogenase Apoptosis Caspase Reactive Oxygen Species (ROS)	Cancer
DHODH-IN-32 (Compound A1) is a DHODH inhibitor. DHODH-IN-32 shows significant cytotoxicity against NCI-60 cell lines, especially being sensitive to breast cancer, prostate cancer and leukemia cell lines. DHODH-IN-32 can induce cell apoptosis by activating the Caspase pathway. DHODH-IN-32 causes G0/G1 phase cell cycle arrest and inhibits cellular metabolism by ROS. DHODH-IN-32 exhibits significant anti-tumor properties in mouse breast cancer models. DHODH-IN-32 can be used for the study of breast cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0083

Leflunomide Maximum Cited Publications 17 Publications Verification HWA486; RS-34821; SU101	Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Dihydroorotate Dehydrogenase Endogenous Metabolite Bacterial
Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

HY-N0157

Orotic acid 3 Publications Verification 6-Carboxyuracil; Vitamin B13	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Endocrine diseases Metabolic Disease Nervous System Disorder Endogenous metabolite Disease Research Fields	Nucleoside Antimetabolite/Analog Endogenous Metabolite
Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

HY-W015495

L-Dihydroorotic acid 1 Publications Verification	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Dihydroorotate Dehydrogenase
L-Dihydroorotic acid is an important intermediate in the metabolism of orotic acid and a substrate of dihydroorotate dehydrogenase (DHODH). L-Dihydroorotic acid can reversibly hydrolyze to yield the acyclic L-ureidosuccinic acid by dihydrowhey enzyme .

HY-N0157R

Orotic acid (Standard) 6-Carboxyuracil (Standard); Vitamin B13 (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite	Reference Standards Nucleoside Antimetabolite/Analog Endogenous Metabolite
Orotic acid (Standard) is the analytical standard of Orotic acid. This product is intended for research and analytical applications. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

HY-N7961

(E/Z)-Ginkgolic acid C17:2	Monophenols Classification of Application Fields Ginkgoaceae Ketones, Aldehydes, Acids Other Diseases Phenols Plants Disease Research Fields Ginkgo biloba Source Classification	Dihydroorotate Dehydrogenase
(E/Z)-Ginkgolic acid C17:2, isolated from Ginkgo biloba, can bind with human dihydroorotate dehydrogenase (DHODH) tightly .

HY-W015495R

L-Dihydroorotic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Dihydroorotate Dehydrogenase
L-Dihydroorotic acid (Standard) is an analytical reference standard for L-Dihydroorotic acid. This product is used for research and analytical applications. L-Dihydroorotic acid is an important intermediate in the metabolism of orotic acid and a substrate of dihydroorotate dehydrogenase (DHODH). L-Dihydroorotic acid can reversibly hydrolyze to yield the acyclic L-ureidosuccinic acid by dihydrowhey enzyme .

HY-N0157A

Orotic acid zinc 3 Publications Verification 6-Carboxyuracil zinc; Vitamin B13 zinc	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Nucleoside Antimetabolite/Analog Endogenous Metabolite
Orotic acid (zinc), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid (zinc) is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid (zinc) can induce hepatic steatosis and hepatomegaly in rats .

HY-B0083R

Leflunomide (Standard) HWA486 (Standard); RS-34821 (Standard); SU101 (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Dihydroorotate Dehydrogenase Endogenous Metabolite Bacterial
Leflunomide (Standard) is the analytical standard of Leflunomide. This product is intended for research and analytical applications. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

HY-N0157AR

Orotic acid zinc (Standard) 6-Carboxyuracil zinc (Standard); Vitamin B13 zinc (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Nucleoside Antimetabolite/Analog Endogenous Metabolite Reference Standards
Orotic acid (zinc) (Standard) is the analytical standard of Orotic acid (zinc). This product is intended for research and analytical applications. Orotic acid (zinc), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid (zinc) is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid (zinc) can induce hepatic steatosis and hepatomegaly in rats .

Cat. No.	Product Name	Chemical Structure

HY-B0083S

Leflunomide-d4
Leflunomide-d₄ (HWA486-d₄) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent .

HY-N0157S1

Orotic acid-13C,15N2 monohydrate

Orotic acid- ¹³C, ¹⁵N₂ (monohydrate) is the ¹³C and ¹⁵N labeled Orotic acid . Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

HY-B0083S1

Leflunomide-13C6
Leflunomide- ¹³C₆ (HWA486- ¹³C₆) is ¹³C labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

HY-108325S

Brequinar-d3
Brequinar-d₃ (DUP785-d₃) is deuterium labeled Brequinar. Brequinar (DUP785) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC₅₀ of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-SARS2 activity .

HY-15510S

Tenovin-6-d6
Tenovin-6-d₆ is the deuterium labeled Tenovin-6 (HY-15510). Tenovin-6, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC₅₀s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 also inhibits dihydroorotate dehydrogenase (DHODH).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks